Share this article
Share this article
RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA
® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11, 3:30 PM-4:15 PM EST).
Share this article
Share this article
RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA
® and ZYTIGA
® plus prednisone (control arm).
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST).
Large Gene panel helpful in identifying cancer-causing genes ANI | Updated: Feb 06, 2021 14:14 IST
Washington [US], February 6 (ANI): Researchers during a recent study have found a gene panel that includes all genes known to potentially cause cancer. This can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML.
The 523-gene panel, which looks about 10 times the number of cancer-causing genes, developed by San Diego-based biotech company Illumina, is currently used to diagnose and fine-tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia. The investigators reported in the journal PLOS ONE.
Share this article
CAMBRIDGE, Mass., Feb. 5, 2021 /PRNewswire/
Outcomes4Me Inc. today announced it is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to extend its patient app to include survivorship care, providing personalized evidence-based resources for patients that have been diagnosed with breast and prostate cancer. The collaboration, made possible by a National Cancer Institute (NCI) contract recently awarded to Outcomes4Me, will include integration into providers workflows to enable oncologists and primary care physicians to generate and manage the survivorship care plan. It will also include integration into the Epic electronic health record (EHR) system used at Vanderbilt University Medical Center.
Organizace NCCN u příležitosti Světového dne rakoviny sdílela osobní příběhy pacientů s cílem zlepšit globální péči o nemocné s nádorovým onemocněním prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.